OMER
Omeros Corporation · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +11.1% ·
share flow +27.2% ·
net new positions +10.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 75 | -1 | 26.88M | $255.76M | +8 | −9 |
| Q1 2026 | 78 | +7 | 23.56M | $249.21M | +9 | −2 |
| Q4 2025 | 71 | -2 | 30.19M | $466.97M | — | −2 |
| Q3 2025 | 17 | 0 | 17.59M | $72.13M | — | — |
| Q2 2025 | 14 | +1 | 14.04M | $42.12M | +1 | — |
| Q1 2025 | 10 | +1 | 6.15M | $50.54M | +1 | — |
| Q4 2024 | 9 | 0 | 4.83M | $47.77M | +1 | −1 |
| Q3 2024 | 8 | +1 | 3.34M | $13.26M | +1 | — |
| Q2 2024 | 7 | — | 3.21M | $13.02M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | D. E. Shaw & Co. ✦ | 1.94M | +5.4% | $15.93M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 2 | D. E. Shaw & Co. ✦ | 1.94M | +5.4% | $15.93M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | D. E. Shaw & Co. ✦ | 1.94M | +5.4% | $15.93M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.37M | +2.2% | $11.26M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 1.37M | +2.2% | $11.26M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | State Street Global Advisors ✦ (passive) | 1.36M | +11.9% | $11.15M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Marshall Wace ✦ | 644.15K | +1357.2% | $5.29M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Marshall Wace ✦ | 644.15K | +1357.2% | $5.29M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Millennium Management ✦ | 315.25K | +268.0% | $2.59M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 173.03K | +137.6% | $1.42M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 11 | Wellington Management ✦ | 136.00K | New | $1.12M | 0.0% | New | 1 | SEC ↗ |
| 12 | Wellington Management ✦ | 136.00K | New | $1.12M | 0.0% | New | 1 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 105.64K | -35.2% | $868,353 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 75.50K | +90.8% | $621,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 34.70K | -11.5% | $285,233 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 34.70K | -11.5% | $285,233 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 34.70K | -11.5% | $285,233 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 34.70K | -11.5% | $285,233 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Wellington Management | $1.12M | 0.0% |
| Wellington Management | $1.12M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 4.17M shares, $8.90M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 906 sh · $17,305
Officer · 10.00K sh · $189,500
Director · 15.00K sh · $276,772
Officer · 5.00K sh · $84,750
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology